Printer Friendly

THE HEALTHCARE SYSTEM IN GERMANY: COMPREHENSIBLE PACKAGE INSERTS TO COME SOON?

 FRANKFURT and MAIN, Germany, March 29 /PRNewswire/ -- "Instructions for the elaboration of package inserts"(A) are to make essential drug information more comprehensible to patients. The instructions worked out by the Association of the German Pharmaceutical Industry (BPI) and the German Federal Health Agency (BGA) are now available. They take into account new requirements on patient information as laid down in EC directives. These requirements have to be incorporated in the German Drug Law (AMG). BPI hopes that this will be done soon so that current package inserts can be replaced by a new and generally more understandable form.
 The instructions contain several patient-friendlyo?rdings. BPI highly values a straightforward structure, the absence of technical terms as well as short and unequivocal phrases, giving clear instructions to patients. In order to directly address patients, headings are to be kept in a simple style and expressed in the form of questions. Furthermore, every point is again explained separately in a standard text.
 Examples:
 -- Interactions: What other medicinal products influence the effect of /../?... Please note that this information may also be relevant to medicinal products administered some time ago.
 -- Contraindicactions: When should /../ not be administered? Please seek medical advice whether you may administer /../ if the following information is not applicable to you at present but was applicable at any time in the past.
 -- Side effects: What side effects can occur in the administration of /../... Side effects are classified using the criteria of frequency and seriousness... The estimated frequency is currently broken down as follows: Frequent (more than 10 percent approx.), occasional (1 percent to 10 percent approx.), rare (less than 1 percent approx.) and isolated cases.
 (A) German: "Anleitung zur Gestaltung von Packungsbeilagen"
 -0- 3/29/93
 /CONTACT: Elke Peters for BPI, in Frankfurt, 69-2556-1220/


CO: Association of the German Pharmaceutical Industry ST: IN: HEA SU:

LR -- NY029 -- 0410 03/29/93 10:21 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 29, 1993
Words:313
Previous Article:COASTAL SUBSIDIARY SIGNS PETROLEUM STORAGE LEASE FOR SUBIC BAY IN THE PHILIPPINES
Next Article:TOYS 'R' US AND WESTERN PUBLISHING ANNOUNCE MAJOR EXPANSION OF BOOKS 'R' US PROGRAM
Topics:


Related Articles
UPJOHN ANNOUNCES NEW U.S. PACKAGING AND LABELING FOR HALCION
Lurgi parent feels financial pinch.
In-mold labeling comes to cut-in-place thermoforming.
/C O R R E C T I O N - CARDINAL HEALTH, INC./(Correction Notice)
West Pharmaceutical Services Files With the FDA to Initiate Human Trials for Ocufit SR(R).
Purdue Pharma Restates Physician Prescribing Information for OxyContin(R) Tablets.
Tooling life improvement wins over a challenging customer.
Berlex Voluntarily Recalls Ultravist(R) Injection 370 mgI/mL.
Movianto Signed Contract With Danish Biotech Company TopoTarget.
Clondalkin makes acquisitions in Canada and USA.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters